<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Korean Circ J</journal-id><journal-id journal-id-type="iso-abbrev">Korean Circ J</journal-id><journal-id journal-id-type="publisher-id">KCJ</journal-id><journal-title-group><journal-title>Korean Circulation Journal</journal-title></journal-title-group><issn pub-type="ppub">1738-5520</issn><issn pub-type="epub">1738-5555</issn><publisher><publisher-name>The Korean Society of Cardiology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24044013</article-id><article-id pub-id-type="pmc">3772299</article-id><article-id pub-id-type="doi">10.4070/kcj.2013.43.8.541</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Genotype- and Phenotype-Directed Personalization of Antiplatelet Treatment in Patients with Non-ST Elevation Acute Coronary Syndromes Undergoing Coronary Stenting</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Sung Gyun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yoon</surname><given-names>Junghan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Juwon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Uh</surname><given-names>Young</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Kyung Min</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Ji Hyun</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Jun-Won</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Youn</surname><given-names>Young Jin</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ahn</surname><given-names>Min-Soo</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jang-Young</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoo</surname><given-names>Byung-Su</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Seung-Hwan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tahk</surname><given-names>Seung-Jea</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Choe</surname><given-names>Kyung-Hoon</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib></contrib-group><aff id="A1"><label>1</label>Division of Cardiology, Yonsei University Wonju College of Medicine, Wonju, Korea.</aff><aff id="A2"><label>2</label>Department of Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea.</aff><aff id="A3"><label>3</label>Department of Cardiology, Ajou University Medical Center, Suwon, Korea.</aff><author-notes><corresp>Correspondence: Junghan Yoon, MD, Division of Cardiology, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju 220-701, Korea. Tel: 82-33-741-0917, Fax: 82-33-741-1219, <email>jyoon@yonsei.ac.kr</email></corresp></author-notes><pub-date pub-type="ppub"><month>8</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>31</day><month>8</month><year>2013</year></pub-date><volume>43</volume><issue>8</issue><fpage>541</fpage><lpage>549</lpage><history><date date-type="received"><day>17</day><month>6</month><year>2013</year></date><date date-type="rev-recd"><day>01</day><month>8</month><year>2013</year></date><date date-type="accepted"><day>06</day><month>8</month><year>2013</year></date></history><permissions><copyright-statement>Copyright © 2013 The Korean Society of Cardiology</copyright-statement><copyright-year>2013</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title><offsets xml_i="5366" xml_f="5391" txt_i="11" txt_f="36">Background and Objectives</offsets></title><p><offsets xml_i="5402" xml_f="5493" txt_i="37" txt_f="128">We evaluated the effectiveness of genotype- and phenotype-directed individualization of P2Y</offsets><sub><offsets xml_i="5498" xml_f="5500" txt_i="128" txt_f="130">12</offsets></sub><offsets xml_i="5506" xml_f="5575" txt_i="130" txt_f="199"> inhibitors to decrease high on-treatment platelet reactivity (HOPR).</offsets></p></sec><sec><title><offsets xml_i="5597" xml_f="5617" txt_i="201" txt_f="221">Subjects and Methods</offsets></title><p><offsets xml_i="5628" xml_f="5840" txt_i="222" txt_f="434">Sixty-five patients undergoing percutaneous coronary intervention for non-ST elevation acute coronary syndromes were randomly assigned to genotype- or phenotype-directed treatment. All patients were screened for </offsets><italic><offsets xml_i="5848" xml_f="5855" txt_i="434" txt_f="441">CYP2C19</offsets><sup><offsets xml_i="5860" xml_f="5861" txt_i="441" txt_f="442">*</offsets></sup><offsets xml_i="5867" xml_f="5868" txt_i="442" txt_f="443">2</offsets></italic><offsets xml_i="5877" xml_f="5879" txt_i="443" txt_f="445">, </offsets><italic><sup><offsets xml_i="5892" xml_f="5893" txt_i="445" txt_f="446">*</offsets></sup><offsets xml_i="5899" xml_f="5900" txt_i="446" txt_f="447">3</offsets></italic><offsets xml_i="5909" xml_f="5914" txt_i="447" txt_f="452">, or </offsets><italic><sup><offsets xml_i="5927" xml_f="5928" txt_i="452" txt_f="453">*</offsets></sup><offsets xml_i="5934" xml_f="5936" txt_i="453" txt_f="455">17</offsets></italic><offsets xml_i="5945" xml_f="6028" txt_i="455" txt_f="538"> alleles by using the Verigene CLO assay (Nanosphere, Northbrook, IL, USA). The P2Y</offsets><sub><offsets xml_i="6033" xml_f="6035" txt_i="538" txt_f="540">12</offsets></sub><offsets xml_i="6041" xml_f="6145" txt_i="540" txt_f="644"> reaction unit (PRU) was measured using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA). 21 </offsets><italic><offsets xml_i="6153" xml_f="6161" txt_i="644" txt_f="652">CYP2C19 </offsets><sup><offsets xml_i="6166" xml_f="6167" txt_i="652" txt_f="653">*</offsets></sup><offsets xml_i="6173" xml_f="6174" txt_i="653" txt_f="654">2</offsets></italic><offsets xml_i="6183" xml_f="6187" txt_i="654" txt_f="658"> or </offsets><italic><sup><offsets xml_i="6200" xml_f="6201" txt_i="658" txt_f="659">*</offsets></sup><offsets xml_i="6207" xml_f="6208" txt_i="659" txt_f="660">3</offsets></italic><offsets xml_i="6217" xml_f="6504" txt_i="660" txt_f="947"> carriers (65.6%) and 11 patients with HOPR (33.3%), defined as a PRU value ≥230, were given 90 mg ticagrelor twice daily; non-carriers and patients without HOPR were given 75 mg clopidogrel daily. The primary endpoint was the percentage of patients with HOPR after 30 days of treatment.</offsets></p></sec><sec><title><offsets xml_i="6526" xml_f="6533" txt_i="949" txt_f="956">Results</offsets></title><p><offsets xml_i="6544" xml_f="7075" txt_i="957" txt_f="1482">PRU decreased following both genotype- and phenotype-directed therapies (242±83 vs. 109±90, p&lt;0.001 in the genotype-directed group; 216±74 vs. 109±90, p=0.001 in the phenotype-directed group). Five subjects (16.2%) in the genotype-directed group and one (3.3%) in the phenotype-directed group had HOPR at day 30 (p=0.086). All patients with HOPR at the baseline who received ticagrelor had a PRU value of &lt;230 after 30 days of treatment. Conversely, clopidogrel did not lower the number of patients with HOPR at the baseline.</offsets></p></sec><sec><title><offsets xml_i="7097" xml_f="7107" txt_i="1484" txt_f="1494">Conclusion</offsets></title><p><offsets xml_i="7118" xml_f="7256" txt_i="1495" txt_f="1633">Tailored antiplatelet therapy according to point-of-care genetic and phenotypic testing may be effective in decreasing HOPR after 30 days.</offsets></p></sec></abstract><kwd-group><kwd>Antiplatelet agents</kwd><kwd>Genetic testing</kwd><kwd>Platelet function tests</kwd><kwd>Point-of-care systems</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="7463" xml_f="7475" txt_i="1642" txt_f="1654">Introduction</offsets></title><p><offsets xml_i="7486" xml_f="7503" txt_i="1655" txt_f="1672">The advent of P2Y</offsets><italic><offsets xml_i="7511" xml_f="7513" txt_i="1672" txt_f="1674">12</offsets></italic><offsets xml_i="7522" xml_f="7982" txt_i="1674" txt_f="2134"> inhibitors with antiplatelet effects has extended the use of the drug-eluting stent (DES) for occlusive coronary artery disease. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel had been considered the standard treatment in patients with acute coronary syndromes (ACSs) undergoing percutaneous coronary intervention (PCI), because DAPT has been shown to reduce the incidence of myocardial infarction (MI) or death from cardiovascular (CV) causes.</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8013" xml_f="8015" txt_i="2134" txt_f="2136">1)</offsets></xref><xref ref-type="bibr" rid="B2"><offsets xml_i="8053" xml_f="8055" txt_i="2136" txt_f="2138">2)</offsets></xref><offsets xml_i="8062" xml_f="8147" txt_i="2138" txt_f="2223"> Nevertheless, the incidence of ischemic events remains high among patients with ACS.</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="8178" xml_f="8180" txt_i="2223" txt_f="2225">3)</offsets></xref></p><p><offsets xml_i="8194" xml_f="8290" txt_i="2226" txt_f="2322">Clopidogrel is a pro-drug that is converted to its active metabolite principally by cytochrome (</offsets><italic><offsets xml_i="8298" xml_f="8301" txt_i="2322" txt_f="2325">CYP</offsets></italic><offsets xml_i="8310" xml_f="8312" txt_i="2325" txt_f="2327">) </offsets><italic><offsets xml_i="8320" xml_f="8328" txt_i="2327" txt_f="2335">P4502C19</offsets></italic><offsets xml_i="8337" xml_f="8416" txt_i="2335" txt_f="2414">, at which time it inhibits platelet activation by irreversibly binding the P2Y</offsets><sub><offsets xml_i="8421" xml_f="8423" txt_i="2414" txt_f="2416">12</offsets></sub><offsets xml_i="8429" xml_f="8465" txt_i="2416" txt_f="2452"> receptor. Genetic polymorphisms in </offsets><italic><offsets xml_i="8473" xml_f="8478" txt_i="2452" txt_f="2457">ABCB1</offsets></italic><offsets xml_i="8487" xml_f="8492" txt_i="2457" txt_f="2462"> and </offsets><italic><offsets xml_i="8500" xml_f="8507" txt_i="2462" txt_f="2469">CYP2C19</offsets></italic><offsets xml_i="8516" xml_f="8903" txt_i="2469" txt_f="2856"> may affect the absorption and metabolism, respectively, of clopidogrel, and consequently alter its pharmacodynamics. As a result, there exists high interindividual variability in the responsiveness to clopidogrel and on-treatment platelet reactivity (OPR). High OPR (HOPR) with clopidogrel use is associated with an increased risk of ischemic events in patients with ACS undergoing PCI.</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8934" xml_f="8935" txt_i="2856" txt_f="2857">4</offsets></xref><offsets xml_i="8942" xml_f="8943" txt_i="2857" txt_f="2858">-</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="8974" xml_f="8976" txt_i="2858" txt_f="2860">6)</offsets></xref></p><p><offsets xml_i="8990" xml_f="9015" txt_i="2861" txt_f="2886">Newer and more potent P2Y</offsets><sub><offsets xml_i="9020" xml_f="9022" txt_i="2886" txt_f="2888">12</offsets></sub><offsets xml_i="9028" xml_f="9274" txt_i="2888" txt_f="3134"> inhibitors, such as prasugrel or ticagrelor, have been shown to be superior to clopidogrel in terms of their ability to decrease ischemic events in patients with ACS. However, their benefits are limited because of increased episodes of bleeding.</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="9305" xml_f="9307" txt_i="3134" txt_f="3136">7)</offsets></xref><xref ref-type="bibr" rid="B8"><offsets xml_i="9345" xml_f="9347" txt_i="3136" txt_f="3138">8)</offsets></xref><offsets xml_i="9354" xml_f="9578" txt_i="3138" txt_f="3362"> Personalization of antiplatelet treatment for ACS may be necessary to attain the maximum inhibition of platelet activation with a minimum risk of bleeding. The recent development of point-of-care assay kits, VerifyNow P2Y12</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="9609" xml_f="9610" txt_i="3362" txt_f="3363">9</offsets></xref><offsets xml_i="9617" xml_f="9618" txt_i="3363" txt_f="3364">-</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="9650" xml_f="9653" txt_i="3364" txt_f="3367">11)</offsets></xref><offsets xml_i="9660" xml_f="9685" txt_i="3367" txt_f="3392"> and Verigene CLO assays,</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="9717" xml_f="9720" txt_i="3392" txt_f="3395">12)</offsets></xref><offsets xml_i="9727" xml_f="9772" txt_i="3395" txt_f="3440"> for the assessment of platelet function and </offsets><italic><offsets xml_i="9780" xml_f="9787" txt_i="3440" txt_f="3447">CYP2C19</offsets></italic><offsets xml_i="9796" xml_f="10042" txt_i="3447" txt_f="3693"> polymorphisms, respectively, has enabled the immediate assignment of individualized antiplatelet treatment. However, as yet, studies using high-dose clopidogrel or prasugrel have not conclusively demonstrated a clinical benefit of the phenotype-</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="10074" xml_f="10077" txt_i="3693" txt_f="3696">10)</offsets></xref><xref ref-type="bibr" rid="B13"><offsets xml_i="10116" xml_f="10119" txt_i="3696" txt_f="3699">13)</offsets></xref><offsets xml_i="10126" xml_f="10187" txt_i="3699" txt_f="3760"> or genotype-directed personalization of antiplatelet therapy</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="10219" xml_f="10222" txt_i="3760" txt_f="3763">14)</offsets></xref><offsets xml_i="10229" xml_f="10288" txt_i="3763" txt_f="3822"> based on residual platelet reactivity, or the presence of </offsets><italic><offsets xml_i="10296" xml_f="10303" txt_i="3822" txt_f="3829">CYP2C19</offsets></italic><offsets xml_i="10312" xml_f="10338" txt_i="3829" txt_f="3855"> loss-of-function alleles.</offsets></p><p><offsets xml_i="10345" xml_f="10748" txt_i="3856" txt_f="4259">Therefore, the aim of this study was to investigate the feasibility of point-of-care genotypic and phenotypic testing to guide individualized antiplatelet therapy using ticagrelor in Korean patients with non-ST elevation ACS undergoing PCI. We also compared the effectiveness of genotype- and phenotype-directed antiplatelet therapy in terms of decreasing the number of patients with HOPR after 30 days.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="10789" xml_f="10809" txt_i="4261" txt_f="4281">Subjects and Methods</offsets></title><sec><title><offsets xml_i="10829" xml_f="10862" txt_i="4282" txt_f="4315">Trial design and study population</offsets></title><p><offsets xml_i="10873" xml_f="10991" txt_i="4316" txt_f="4434">The present study was a single center, prospective, randomized, proof-of-concept trial. The study flow is as shown in </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="11021" xml_f="11027" txt_i="4434" txt_f="4440">Fig. 1</offsets></xref><offsets xml_i="11034" xml_f="11203" txt_i="4440" txt_f="4609">. The study protocol was approved by the Ethical Review Board of Yonsei Severance Christian Hospital (Wonju, Korea). Informed consent was obtained from all participants.</offsets></p><p><offsets xml_i="11210" xml_f="12083" txt_i="4610" txt_f="5471">Between April 10, 2012 and February 6, 2013, 65 patients aged 18-75 years were randomly assigned to genotype- or phenotype-directed treatment according to a random-number table. Patients were eligible if they had undergone PCI for non-ST-elevation ACS. Patients presenting with ST-segment elevation myocardial infarction and who had had severe left ventricular dysfunction (ejection fraction, &lt;30%) or cardiogenic shock were excluded from the study. Other exclusion criteria were bradyarrhythmia, a history of transient ischemic or cerebrovascular attacks, a platelet count of &lt;150000/mL, hematocrit of &lt;30%, and a creatinine clearance rate of &lt;30 mL/min. Patients who received a periprocedural thrombolytic agent or glycoprotein IIb-IIIa inhibitor, or who planned to use oral anticoagulants or other antiplatelet agents, such as cilostazol, were also excluded.</offsets></p></sec><sec><title><offsets xml_i="12105" xml_f="12125" txt_i="5473" txt_f="5493">VerifyNow P2Y12 test</offsets></title><p><offsets xml_i="12136" xml_f="12408" txt_i="5494" txt_f="5766">On-treatment platelet reactivity was measured using the VerifyNow P2Y12 assay (Accumetrics, San Diego, CA, USA). Blood samples were obtained 12 to 24 hours after PCI and after a 30-day follow-up period. Each sample was placed in a tube containing 3.2% citrate, and the P2Y</offsets><sub><offsets xml_i="12413" xml_f="12415" txt_i="5766" txt_f="5768">12</offsets></sub><offsets xml_i="12421" xml_f="12501" txt_i="5768" txt_f="5848"> reaction unit (PRU) value was assessed within 2 hours, as previously described.</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="12533" xml_f="12536" txt_i="5848" txt_f="5851">11)</offsets></xref><offsets xml_i="12543" xml_f="12634" txt_i="5851" txt_f="5942"> HOPR was defined as PRU value ≥230 based on previous studies involving Caucasian subjects.</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="12665" xml_f="12667" txt_i="5942" txt_f="5944">9)</offsets></xref><xref ref-type="bibr" rid="B15"><offsets xml_i="12706" xml_f="12709" txt_i="5944" txt_f="5947">15)</offsets></xref><offsets xml_i="12716" xml_f="12873" txt_i="5947" txt_f="6104"> Although studies conducted among Korean subjects revealed that HOPR of an approximate PRU value of 270 is necessary to predict future cardiovascular events,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="12904" xml_f="12906" txt_i="6104" txt_f="6106">4)</offsets></xref><xref ref-type="bibr" rid="B16"><offsets xml_i="12945" xml_f="12948" txt_i="6106" txt_f="6109">16)</offsets></xref><xref ref-type="bibr" rid="B17"><offsets xml_i="12987" xml_f="12990" txt_i="6109" txt_f="6112">17)</offsets></xref><offsets xml_i="12997" xml_f="13141" txt_i="6112" txt_f="6256"> we selected a PRU value of 230 as the cutoff, in order to include more patients who might benefit from phenotype-directed antiplatelet therapy.</offsets></p></sec><sec><title><offsets xml_i="13163" xml_f="13181" txt_i="6258" txt_f="6276">Verigene CLO assay</offsets></title><p><offsets xml_i="13192" xml_f="13227" txt_i="6277" txt_f="6312">All patients were screened for the </offsets><italic><offsets xml_i="13235" xml_f="13242" txt_i="6312" txt_f="6319">CYP2C19</offsets><sup><offsets xml_i="13247" xml_f="13248" txt_i="6319" txt_f="6320">*</offsets></sup><offsets xml_i="13254" xml_f="13255" txt_i="6320" txt_f="6321">2</offsets></italic><offsets xml_i="13264" xml_f="13266" txt_i="6321" txt_f="6323">, </offsets><italic><sup><offsets xml_i="13279" xml_f="13280" txt_i="6323" txt_f="6324">*</offsets></sup><offsets xml_i="13286" xml_f="13287" txt_i="6324" txt_f="6325">3</offsets></italic><offsets xml_i="13296" xml_f="13301" txt_i="6325" txt_f="6330">, or </offsets><italic><sup><offsets xml_i="13314" xml_f="13315" txt_i="6330" txt_f="6331">*</offsets></sup><offsets xml_i="13321" xml_f="13323" txt_i="6331" txt_f="6333">17</offsets></italic><offsets xml_i="13332" xml_f="13857" txt_i="6333" txt_f="6858"> allele by using the Verigene CLO assay (Nanosphere, Northbrook, IL, USA). The Verigene CLO assay is an automated sample-to-result microarray-based assay in which deoxyribonucleic acid (DNA) extracted from whole blood samples is hybridized to allele-specific probes immobilized on a glass slide. The detection of captured DNA is achieved using nanoparticle-conjugated probes that have been demonstrated to provide excellent sensitivity and that eliminate the need for a target amplification step prior to array hybridization.</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="13889" xml_f="13892" txt_i="6858" txt_f="6861">18)</offsets></xref><offsets xml_i="13899" xml_f="13973" txt_i="6861" txt_f="6935"> The Verigene CLO assay accurately identified homozygous and heterozygous </offsets><italic><sup><offsets xml_i="13986" xml_f="13987" txt_i="6935" txt_f="6936">*</offsets></sup><offsets xml_i="13993" xml_f="13994" txt_i="6936" txt_f="6937">2</offsets></italic><offsets xml_i="14003" xml_f="14008" txt_i="6937" txt_f="6942"> and </offsets><italic><sup><offsets xml_i="14021" xml_f="14022" txt_i="6942" txt_f="6943">*</offsets></sup><offsets xml_i="14028" xml_f="14029" txt_i="6943" txt_f="6944">3</offsets></italic><offsets xml_i="14038" xml_f="14181" txt_i="6944" txt_f="7087"> phenotypes with a specificity of 100% and a final call rate of 99.7%. The assay is automated and can yield results in approximately 3.5 hours.</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="14213" xml_f="14216" txt_i="7087" txt_f="7090">19)</offsets></xref></p></sec><sec><title><offsets xml_i="14245" xml_f="14301" txt_i="7092" txt_f="7148">Phenotype- versus genotype-directed antiplatelet regimen</offsets></title><p><offsets xml_i="14312" xml_f="14913" txt_i="7149" txt_f="7750">Regardless of their prior exposure to clopidogrel, all patients received 300 mg of aspirin and 300 mg of clopidogrel before arriving at the catheterization room. A bolus of unfractionated heparin (70 U/kg) was administered immediately before coronary angiography through the introducer sheath. A second bolus of unfractionated heparin (70 U/kg) was administered immediately before the PCI. Additional heparin was administered to achieve an activated clotting time of 250-300 seconds. PCI was performed using balloon predilatation, followed by DES deployment via the transradial or transfemoral artery.</offsets></p><p><offsets xml_i="14920" xml_f="15112" txt_i="7751" txt_f="7943">The choice regarding the specific type of DES was left to be determined by the operator's discretion. All patients were given 100 mg of aspirin daily after PCI. Patients with HOPR or who were </offsets><italic><offsets xml_i="15120" xml_f="15128" txt_i="7943" txt_f="7951">CYP2C19 </offsets><sup><offsets xml_i="15133" xml_f="15134" txt_i="7951" txt_f="7952">*</offsets></sup><offsets xml_i="15140" xml_f="15141" txt_i="7952" txt_f="7953">2</offsets></italic><offsets xml_i="15150" xml_f="15154" txt_i="7953" txt_f="7957"> or </offsets><italic><sup><offsets xml_i="15167" xml_f="15168" txt_i="7957" txt_f="7958">*</offsets></sup><offsets xml_i="15174" xml_f="15175" txt_i="7958" txt_f="7959">3</offsets></italic><offsets xml_i="15184" xml_f="15329" txt_i="7959" txt_f="8104"> carriers were also given 90 mg of ticagrelor twice daily. Patients without HOPR or who were non-carriers were given 75 mg of clopidogrel daily (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="15359" xml_f="15365" txt_i="8104" txt_f="8110">Fig. 1</offsets></xref><offsets xml_i="15372" xml_f="15374" txt_i="8110" txt_f="8112">).</offsets></p></sec><sec><title><offsets xml_i="15396" xml_f="15421" txt_i="8114" txt_f="8139">Definitions and endpoints</offsets></title><p><offsets xml_i="15432" xml_f="15665" txt_i="8140" txt_f="8373">The primary endpoint was the percentage of patients with HOPR after 30 days of DAPT. The secondary endpoints were 1) PRU, ΔPRU, percent inhibition of platelet aggregation (%IPA), and Δ%IPA, 2) the correlation between the presence of </offsets><italic><offsets xml_i="15673" xml_f="15681" txt_i="8373" txt_f="8381">CYP2C19 </offsets><sup><offsets xml_i="15686" xml_f="15687" txt_i="8381" txt_f="8382">*</offsets></sup><offsets xml_i="15693" xml_f="15694" txt_i="8382" txt_f="8383">2</offsets></italic><offsets xml_i="15703" xml_f="15707" txt_i="8383" txt_f="8387"> or </offsets><italic><sup><offsets xml_i="15720" xml_f="15721" txt_i="8387" txt_f="8388">*</offsets></sup><offsets xml_i="15727" xml_f="15728" txt_i="8388" txt_f="8389">3</offsets></italic><offsets xml_i="15737" xml_f="15868" txt_i="8389" txt_f="8520"> carriers and HOPR at the baseline, 3) the incidence of bleeding using the Bleeding Academic Research Consortium (BARC) definition,</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="15900" xml_f="15903" txt_i="8520" txt_f="8523">20)</offsets></xref><offsets xml_i="15910" xml_f="16107" txt_i="8523" txt_f="8720"> and 4) major adverse cardiac events (MACEs) defined as the composite of death from CV causes, non-fatal myocardial infarction, ischemia-driven target lesion revascularization, or stent thrombosis.</offsets></p></sec><sec><title><offsets xml_i="16129" xml_f="16149" txt_i="8722" txt_f="8742">Statistical analysis</offsets></title><p><offsets xml_i="16160" xml_f="16271" txt_i="8743" txt_f="8854">The proportion of patients with HOPR after 1 month of DAPT in the genotype-directed group was assumed to be 5%.</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="16303" xml_f="16306" txt_i="8854" txt_f="8857">14)</offsets></xref><offsets xml_i="16313" xml_f="17584" txt_i="8857" txt_f="10122"> On a ratio basis of 80%, we calculated that we needed 44 subjects per group to detect a 20% difference between the groups. The test statistic used was the two-sided Z test with pooled variance. The significance level of the test was targeted at 0.05. Assuming a dropout rate of 14%, we would therefore need 50 patients each in the genotype- and phenotype-directed groups, forming a total of 100 patients. Enrollment was ceased at 65 patients because the number of Verigene CLO assay kits was insufficient. Analysis was based on intent-to-treat or per-treatment where necessary. All continuous variables are presented as mean±SD and were analyzed using the Student's t-test. Categorical variables are presented as frequencies (percentage), and were analyzed using the chi-square test or Fisher's exact test. OPR was compared based upon the genotype using one-way analysis of variance. Post-hoc analysis was performed for any parameters found to be p&lt;0.05. We compared platelet reactivity at the baseline and after 30 days in the genotype- and phenotype-directed groups by using the Student's t-test. The significance level was defined as p&lt;0.05. All analyses were performed with Statistical Package for the Social Sciences (SPSS) 20.0 (SPSS Inc., Chicago, IL, USA).</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="17631" xml_f="17638" txt_i="10125" txt_f="10132">Results</offsets></title><p><offsets xml_i="17649" xml_f="17703" txt_i="10133" txt_f="10187">Of the 32 patients in the genotype-directed group, 21 </offsets><italic><offsets xml_i="17711" xml_f="17719" txt_i="10187" txt_f="10195">CYP2C19 </offsets><sup><offsets xml_i="17724" xml_f="17725" txt_i="10195" txt_f="10196">*</offsets></sup><offsets xml_i="17731" xml_f="17732" txt_i="10196" txt_f="10197">2</offsets></italic><offsets xml_i="17741" xml_f="17745" txt_i="10197" txt_f="10201"> or </offsets><italic><sup><offsets xml_i="17758" xml_f="17759" txt_i="10201" txt_f="10202">*</offsets></sup><offsets xml_i="17765" xml_f="17766" txt_i="10202" txt_f="10203">3</offsets></italic><offsets xml_i="17775" xml_f="17829" txt_i="10203" txt_f="10257"> carriers (65.6%) were administered ticagrelor and 11 </offsets><italic><offsets xml_i="17837" xml_f="17845" txt_i="10257" txt_f="10265">CYP2C19 </offsets><sup><offsets xml_i="17850" xml_f="17851" txt_i="10265" txt_f="10266">*</offsets></sup><offsets xml_i="17857" xml_f="17858" txt_i="10266" txt_f="10267">2</offsets></italic><offsets xml_i="17867" xml_f="17871" txt_i="10267" txt_f="10271"> or </offsets><italic><sup><offsets xml_i="17884" xml_f="17885" txt_i="10271" txt_f="10272">*</offsets></sup><offsets xml_i="17891" xml_f="17892" txt_i="10272" txt_f="10273">3</offsets></italic><offsets xml_i="17901" xml_f="18602" txt_i="10273" txt_f="10974"> non-carriers (34.4%) were administered clopidogrel. Of the 33 patients in the phenotype-directed group, 11 patients with HOPR (33.3%) were administered ticagrelor and 22 patients without HOPR (66.7%) were administered clopidogrel. In the genotype-directed group, there were five crossover cases from ticagrelor to clopidogrel because of dyspnea (2 patients), nasal bleeding (1 patient), petechia on the whole body (1 patient), and generalized rash (1 patient). In the phenotype-directed group, one crossover from ticagrelor to clopidogrel occurred due to dyspnea. Sixty-one patients (95.3%) had follow-up VerifyNow P2Y12 assay, 31 and 30 in the genotype- and phenotype-directed groups, respectively (</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="18632" xml_f="18638" txt_i="10974" txt_f="10980">Fig. 1</offsets></xref><offsets xml_i="18645" xml_f="18647" txt_i="10980" txt_f="10982">).</offsets></p><p><offsets xml_i="18654" xml_f="18739" txt_i="10983" txt_f="11068">Baseline clinical and procedural characteristics between the groups are presented in </offsets><xref ref-type="table" rid="T1"><offsets xml_i="18771" xml_f="18778" txt_i="11068" txt_f="11075">Table 1</offsets></xref><offsets xml_i="18785" xml_f="19591" txt_i="11075" txt_f="11881">. The two groups were balanced with respect to age, sex, and histories of diabetes mellitus, hypertension, hyperlipidemia, smoking, and myocardial infarction. The distribution of discharge medication use between the two groups was similar, except for the use of clopidogrel and ticagrelor. Clopidogrel was taken more frequently and ticagrelor less frequently by patients in the phenotype-guided group (clopidogrel: 34.4% vs. 66.7%, genotype vs. phenotype, p=0.009; ticagrelor: 65.6% vs. 33.3%, genotype vs. phenotype, p=0.009). The indications for PCI, left ventricular ejection fraction, and distribution of vessels stented did not differ between the groups. Procedural variables including the extent of coronary artery disease, stent number, total stent length, and mean stent diameter were also similar.</offsets></p><sec><title><offsets xml_i="19607" xml_f="19653" txt_i="11882" txt_f="11928">Comparison of on-treatment platelet reactivity</offsets></title><p><offsets xml_i="19664" xml_f="19751" txt_i="11929" txt_f="12016">The comparison of OPR according to the personalization strategy of DAPT is as shown in </offsets><xref ref-type="table" rid="T2"><offsets xml_i="19783" xml_f="19790" txt_i="12016" txt_f="12023">Table 2</offsets></xref><offsets xml_i="19797" xml_f="20556" txt_i="12023" txt_f="12779">. At the baseline, there were no differences in OPR, %IPA, and the percentage of patients with HOPR between the groups. OPR decreased following both genotype- and phenotype-directed therapies (242±83 vs. 109±90, p&lt;0.001 in the genotype-directed group; 216±74 vs. 109±90, p=0.001 in the phenotype-directed group). At day 30, the percentage of patient with HOPR tended to be higher in the genotype-directed group (16.2% vs. 3.3%, p=0.086). At the 30-day follow-up, PRU and %IPA were similar between the two groups. However, ΔPRU was higher in the genotype- versus the phenotype-directed group (156±115 vs. 83±124, p=0.027). This may be due to the fact that more patients were administered ticagrelor in the genotype-directed group (51.6% vs. 33.3%, p=0.009).</offsets></p></sec><sec><title><offsets xml_i="20578" xml_f="20624" txt_i="12781" txt_f="12827">On-treatment platelet reactivity according to </offsets><italic><offsets xml_i="20632" xml_f="20639" txt_i="12827" txt_f="12834">CYP2C19</offsets></italic><offsets xml_i="20648" xml_f="20657" txt_i="12834" txt_f="12843"> genotype</offsets></title><p><offsets xml_i="20668" xml_f="20720" txt_i="12844" txt_f="12896">Approximately 35% of patients were heterozygous for </offsets><italic><offsets xml_i="20728" xml_f="20736" txt_i="12896" txt_f="12904">CYP2C19 </offsets><sup><offsets xml_i="20741" xml_f="20742" txt_i="12904" txt_f="12905">*</offsets></sup><offsets xml_i="20748" xml_f="20749" txt_i="12905" txt_f="12906">2</offsets></italic><offsets xml_i="20758" xml_f="20762" txt_i="12906" txt_f="12910"> or </offsets><italic><sup><offsets xml_i="20775" xml_f="20776" txt_i="12910" txt_f="12911">*</offsets></sup><offsets xml_i="20782" xml_f="20783" txt_i="12911" txt_f="12912">3</offsets></italic><offsets xml_i="20792" xml_f="20818" txt_i="12912" txt_f="12938">. 23% were homozygous for </offsets><italic><offsets xml_i="20826" xml_f="20834" txt_i="12938" txt_f="12946">CYP2C19 </offsets><sup><offsets xml_i="20839" xml_f="20840" txt_i="12946" txt_f="12947">*</offsets></sup><offsets xml_i="20846" xml_f="20847" txt_i="12947" txt_f="12948">2</offsets></italic><offsets xml_i="20856" xml_f="20877" txt_i="12948" txt_f="12969"> or were carriers of </offsets><italic><offsets xml_i="20885" xml_f="20893" txt_i="12969" txt_f="12977">CYP2C19 </offsets><sup><offsets xml_i="20898" xml_f="20899" txt_i="12977" txt_f="12978">*</offsets></sup><offsets xml_i="20905" xml_f="20906" txt_i="12978" txt_f="12979">2</offsets></italic><offsets xml_i="20915" xml_f="20916" txt_i="12979" txt_f="12980">/</offsets><italic><sup><offsets xml_i="20929" xml_f="20930" txt_i="12980" txt_f="12981">*</offsets></sup><offsets xml_i="20936" xml_f="20937" txt_i="12981" txt_f="12982">3</offsets></italic><offsets xml_i="20946" xml_f="20948" txt_i="12982" txt_f="12984"> (</offsets><xref ref-type="table" rid="T3"><offsets xml_i="20980" xml_f="20987" txt_i="12984" txt_f="12991">Table 3</offsets></xref><offsets xml_i="20994" xml_f="21044" txt_i="12991" txt_f="13041">). Baseline OPR was higher in patients expressing </offsets><italic><offsets xml_i="21052" xml_f="21060" txt_i="13041" txt_f="13049">CYP2C19 </offsets><sup><offsets xml_i="21065" xml_f="21066" txt_i="13049" txt_f="13050">*</offsets></sup><offsets xml_i="21072" xml_f="21073" txt_i="13050" txt_f="13051">2</offsets></italic><offsets xml_i="21082" xml_f="21083" txt_i="13051" txt_f="13052">/</offsets><italic><sup><offsets xml_i="21096" xml_f="21097" txt_i="13052" txt_f="13053">*</offsets></sup><offsets xml_i="21103" xml_f="21104" txt_i="13053" txt_f="13054">2</offsets></italic><offsets xml_i="21113" xml_f="21117" txt_i="13054" txt_f="13058"> or </offsets><italic><offsets xml_i="21125" xml_f="21133" txt_i="13058" txt_f="13066">CYP2C19 </offsets><sup><offsets xml_i="21138" xml_f="21139" txt_i="13066" txt_f="13067">*</offsets></sup><offsets xml_i="21145" xml_f="21146" txt_i="13067" txt_f="13068">2</offsets></italic><offsets xml_i="21155" xml_f="21156" txt_i="13068" txt_f="13069">/</offsets><italic><sup><offsets xml_i="21169" xml_f="21170" txt_i="13069" txt_f="13070">*</offsets></sup><offsets xml_i="21176" xml_f="21177" txt_i="13070" txt_f="13071">3</offsets></italic><offsets xml_i="21186" xml_f="21237" txt_i="13071" txt_f="13122"> compared to that in patients expressing wild-type </offsets><italic><offsets xml_i="21245" xml_f="21253" txt_i="13122" txt_f="13130">CYP2C19 </offsets><sup><offsets xml_i="21258" xml_f="21259" txt_i="13130" txt_f="13131">*</offsets></sup><offsets xml_i="21265" xml_f="21266" txt_i="13131" txt_f="13132">1</offsets></italic><offsets xml_i="21275" xml_f="21276" txt_i="13132" txt_f="13133">/</offsets><italic><sup><offsets xml_i="21289" xml_f="21290" txt_i="13133" txt_f="13134">*</offsets></sup><offsets xml_i="21296" xml_f="21297" txt_i="13134" txt_f="13135">1</offsets></italic><offsets xml_i="21306" xml_f="21310" txt_i="13135" txt_f="13139"> or </offsets><italic><offsets xml_i="21318" xml_f="21325" txt_i="13139" txt_f="13146">CYP2C19</offsets><sup><offsets xml_i="21330" xml_f="21331" txt_i="13146" txt_f="13147">*</offsets></sup><offsets xml_i="21337" xml_f="21338" txt_i="13147" txt_f="13148">1</offsets></italic><offsets xml_i="21347" xml_f="21348" txt_i="13148" txt_f="13149">/</offsets><italic><sup><offsets xml_i="21361" xml_f="21362" txt_i="13149" txt_f="13150">*</offsets></sup><offsets xml_i="21368" xml_f="21370" txt_i="13150" txt_f="13152">17</offsets></italic><offsets xml_i="21379" xml_f="21413" txt_i="13152" txt_f="13186"> and in patients heterozygous for </offsets><italic><offsets xml_i="21421" xml_f="21429" txt_i="13186" txt_f="13194">CYP2C19 </offsets><sup><offsets xml_i="21434" xml_f="21435" txt_i="13194" txt_f="13195">*</offsets></sup><offsets xml_i="21441" xml_f="21442" txt_i="13195" txt_f="13196">2</offsets></italic><offsets xml_i="21451" xml_f="21455" txt_i="13196" txt_f="13200"> or </offsets><italic><sup><offsets xml_i="21468" xml_f="21469" txt_i="13200" txt_f="13201">*</offsets></sup><offsets xml_i="21475" xml_f="21476" txt_i="13201" txt_f="13202">3</offsets></italic><offsets xml_i="21485" xml_f="21577" txt_i="13202" txt_f="13294"> (280±50 vs. 214±80, p=0.004). However, no difference was found in the baseline OPR between </offsets><italic><offsets xml_i="21585" xml_f="21593" txt_i="13294" txt_f="13302">CYP2C19 </offsets><sup><offsets xml_i="21598" xml_f="21599" txt_i="13302" txt_f="13303">*</offsets></sup><offsets xml_i="21605" xml_f="21606" txt_i="13303" txt_f="13304">2</offsets></italic><offsets xml_i="21615" xml_f="21619" txt_i="13304" txt_f="13308"> or </offsets><italic><sup><offsets xml_i="21632" xml_f="21633" txt_i="13308" txt_f="13309">*</offsets></sup><offsets xml_i="21639" xml_f="21640" txt_i="13309" txt_f="13310">3</offsets></italic><offsets xml_i="21649" xml_f="21690" txt_i="13310" txt_f="13351"> non-carriers and those heterozygous for </offsets><italic><offsets xml_i="21698" xml_f="21706" txt_i="13351" txt_f="13359">CYP2C19 </offsets><sup><offsets xml_i="21711" xml_f="21712" txt_i="13359" txt_f="13360">*</offsets></sup><offsets xml_i="21718" xml_f="21719" txt_i="13360" txt_f="13361">2</offsets></italic><offsets xml_i="21728" xml_f="21732" txt_i="13361" txt_f="13365"> or </offsets><italic><sup><offsets xml_i="21745" xml_f="21746" txt_i="13365" txt_f="13366">*</offsets></sup><offsets xml_i="21752" xml_f="21753" txt_i="13366" txt_f="13367">3</offsets></italic><offsets xml_i="21762" xml_f="21881" txt_i="13367" txt_f="13486"> (217±84 vs. 209±78, p=0.880). After 30 days, ΔOPR from the baseline to follow-up was higher among patients expressing </offsets><italic><offsets xml_i="21889" xml_f="21897" txt_i="13486" txt_f="13494">CYP2C19 </offsets><sup><offsets xml_i="21902" xml_f="21903" txt_i="13494" txt_f="13495">*</offsets></sup><offsets xml_i="21909" xml_f="21910" txt_i="13495" txt_f="13496">2</offsets></italic><offsets xml_i="21919" xml_f="21920" txt_i="13496" txt_f="13497">/</offsets><italic><sup><offsets xml_i="21933" xml_f="21934" txt_i="13497" txt_f="13498">*</offsets></sup><offsets xml_i="21940" xml_f="21941" txt_i="13498" txt_f="13499">2</offsets></italic><offsets xml_i="21950" xml_f="21954" txt_i="13499" txt_f="13503"> or </offsets><italic><offsets xml_i="21962" xml_f="21970" txt_i="13503" txt_f="13511">CYP2C19 </offsets><sup><offsets xml_i="21975" xml_f="21976" txt_i="13511" txt_f="13512">*</offsets></sup><offsets xml_i="21982" xml_f="21983" txt_i="13512" txt_f="13513">2</offsets></italic><offsets xml_i="21992" xml_f="21993" txt_i="13513" txt_f="13514">/</offsets><italic><sup><offsets xml_i="22006" xml_f="22007" txt_i="13514" txt_f="13515">*</offsets></sup><offsets xml_i="22013" xml_f="22014" txt_i="13515" txt_f="13516">3</offsets></italic><offsets xml_i="22023" xml_f="22098" txt_i="13516" txt_f="13591">, corresponding with a greater percentage of patients receiving ticagrelor.</offsets></p></sec><sec><title><offsets xml_i="22120" xml_f="22199" txt_i="13593" txt_f="13672">On-treatment platelet reactivity according to clopidogrel versus ticagrelor use</offsets></title><p><offsets xml_i="22210" xml_f="22437" txt_i="13673" txt_f="13900">The number of patients with HOPR at baseline was greater in those allocated ticagrelor; however, none had HOPR after 30 days of treatment. The number of patients with HOPR did not change after 30 days of clopidogrel treatment (</offsets><xref ref-type="table" rid="T4"><offsets xml_i="22469" xml_f="22476" txt_i="13900" txt_f="13907">Table 4</offsets></xref><offsets xml_i="22483" xml_f="22694" txt_i="13907" txt_f="14115">). Baseline OPR was significantly higher in patients slated to receive ticagrelor. After 30 days of treatment, OPR was lower (49±30 vs. 179±77, p&lt;0.001) in patients taking ticagrelor compared to clopidogrel (</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="22724" xml_f="22730" txt_i="14115" txt_f="14121">Fig. 2</offsets></xref><offsets xml_i="22737" xml_f="22854" txt_i="14121" txt_f="14235">); accordingly, ΔPRU from baseline to follow-up was higher (84±9 vs. 34±26, p&lt;0.001) in patients given ticagrelor.</offsets></p><p><offsets xml_i="22861" xml_f="23043" txt_i="14236" txt_f="14418">There were no MACEs in either group during the 1-month follow-up period. There were two nuisance BARC type 2 bleeding events in the genotype-directed group related to ticagrelor use.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="23093" xml_f="23103" txt_i="14421" txt_f="14431">Discussion</offsets></title><p><offsets xml_i="23114" xml_f="23551" txt_i="14432" txt_f="14869">This was the first study that demonstrated the feasibility and effectiveness of anti-platelet therapy tailored by point-of-care genetic or platelet function testing to decrease the OPR in patients undergoing PCI. The major findings in the present study were that OPR was effectively decreased following both genotype- and phenotype-directed therapy and compared to clopidogrel, ticagrelor caused higher decrease in OPR regardless of the </offsets><italic><offsets xml_i="23559" xml_f="23566" txt_i="14869" txt_f="14876">CYP2C19</offsets></italic><offsets xml_i="23575" xml_f="23585" txt_i="14876" txt_f="14886"> genotype.</offsets></p><p><offsets xml_i="23592" xml_f="24101" txt_i="14887" txt_f="15396">Heightened platelet reactivity contributes to the occurrence of ischemic events especially in certain clinical subsets such as ACS, chronic kidney disease, or diabetes mellitus. HOPR with clopidogrel treatment has also been proposed to be a predictor of ischemic CV events in patients undergoing DES implantation. To date, there is little consensus on the treatment options to overcome HOPR. Studies examining the effect of high- versus standard-dose clopidogrel have yielded discrepant findings. Mehta et al.</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="24133" xml_f="24136" txt_i="15396" txt_f="15399">21)</offsets></xref><offsets xml_i="24143" xml_f="24259" txt_i="15399" txt_f="15515"> noted a reduction in CV events and stent thrombosis in patients given double-dose clopidogrel, whereas Price et al.</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="24291" xml_f="24294" txt_i="15515" txt_f="15518">10)</offsets></xref><offsets xml_i="24301" xml_f="24346" txt_i="15518" txt_f="15563"> found no effect on CV outcomes. Price et al.</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="24378" xml_f="24381" txt_i="15563" txt_f="15566">10)</offsets></xref><offsets xml_i="24388" xml_f="24496" txt_i="15566" txt_f="15674"> attributed this difference to the selection only of patients with HOPR in their study, whereas Mehta et al.</offsets><xref ref-type="bibr" rid="B21"><offsets xml_i="24528" xml_f="24531" txt_i="15674" txt_f="15677">21)</offsets></xref><offsets xml_i="24538" xml_f="24783" txt_i="15677" txt_f="15922"> enrolled patients regardless of platelet reactivity. Although the addition of cilostazol to DAPT lowered PRU levels more than DAPT, the effect of triple versus double therapy on composite CV outcomes was inconsistent in patients undergoing PCI.</offsets><xref ref-type="bibr" rid="B22"><offsets xml_i="24815" xml_f="24818" txt_i="15922" txt_f="15925">22)</offsets></xref><xref ref-type="bibr" rid="B23"><offsets xml_i="24857" xml_f="24860" txt_i="15925" txt_f="15928">23)</offsets></xref><offsets xml_i="24867" xml_f="25058" txt_i="15928" txt_f="16119"> The more potent antiplatelet agents, prasugrel or ticagrelor, have been shown to be superior to clopidogrel in terms of reducing CV events, but with a higher occurrence of bleeding episodes,</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="25089" xml_f="25091" txt_i="16119" txt_f="16121">7)</offsets></xref><xref ref-type="bibr" rid="B8"><offsets xml_i="25129" xml_f="25131" txt_i="16121" txt_f="16123">8)</offsets></xref><offsets xml_i="25138" xml_f="25191" txt_i="16123" txt_f="16176"> which is associated with a higher risk of CV events.</offsets><xref ref-type="bibr" rid="B24"><offsets xml_i="25223" xml_f="25226" txt_i="16176" txt_f="16179">24)</offsets></xref><offsets xml_i="25233" xml_f="25748" txt_i="16179" txt_f="16694"> In the present study, ticagrelor substantially reduced OPR after 30 days. However, two patients ceased taking ticagrelor use because of nasal bleeding and the appearance of petechiae on the whole body. Because of the concern of the increased risk of bleeding, the use of parasugrel or ticagrelor is not yet widespread in Korea, even among the ACS population after PCI. Further study is therefore warranted on the effects of reduced doses of prasugrel or ticagrelor on the clinical endpoints in Korean ACS patients.</offsets></p><p><offsets xml_i="25755" xml_f="26084" txt_i="16695" txt_f="17024">The use of point-of-care testing to tailor antiplatelet therapy according to risk stratification for bleeding and ischemia represents an ideal strategy for ACS patients. Among these tests, the VerifyNow P2Y12 assay to measure OPR is increasingly being used given the evidence suggesting an association between HOPR and CV events.</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="26115" xml_f="26117" txt_i="17024" txt_f="17026">9)</offsets></xref><xref ref-type="bibr" rid="B15"><offsets xml_i="26156" xml_f="26159" txt_i="17026" txt_f="17029">15)</offsets></xref><offsets xml_i="26166" xml_f="26293" txt_i="17029" txt_f="17156"> However, there are several shortcomings to measuring OPR: 1) OPR is a surrogate marker only representing the inhibition of P2Y</offsets><sub><offsets xml_i="26298" xml_f="26300" txt_i="17156" txt_f="17158">12</offsets></sub><offsets xml_i="26306" xml_f="26536" txt_i="17158" txt_f="17388"> receptor mediated platelet activation, not whole platelet activity; 2) OPR cannot be measured in patients treated with glycoprotein IIb-IIIa inhibitors or thrombolytics; 3) PRU value varies with elapsed time following ACS or PCI;</offsets><xref ref-type="bibr" rid="B25"><offsets xml_i="26568" xml_f="26571" txt_i="17388" txt_f="17391">25)</offsets></xref><xref ref-type="bibr" rid="B26"><offsets xml_i="26610" xml_f="26613" txt_i="17391" txt_f="17394">26)</offsets></xref><offsets xml_i="26620" xml_f="26682" txt_i="17394" txt_f="17456"> 4) the cutoff for HOPR varies according to patient ethnicity;</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="26713" xml_f="26715" txt_i="17456" txt_f="17458">4)</offsets></xref><xref ref-type="bibr" rid="B16"><offsets xml_i="26754" xml_f="26757" txt_i="17458" txt_f="17461">16)</offsets></xref><offsets xml_i="26764" xml_f="27043" txt_i="17461" txt_f="17740"> and 5) the relationship between low OPR and bleeding events has yet to be definitively established. Moreover, trials in which antiplatelet therapy has been personalized according to the results of the VerifyNow P2Y12 assay have failed to demonstrate any improvement in outcomes.</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="27075" xml_f="27078" txt_i="17740" txt_f="17743">10)</offsets></xref><xref ref-type="bibr" rid="B13"><offsets xml_i="27117" xml_f="27120" txt_i="17743" txt_f="17746">13)</offsets></xref><xref ref-type="bibr" rid="B27"><offsets xml_i="27159" xml_f="27162" txt_i="17746" txt_f="17749">27)</offsets></xref></p><p><offsets xml_i="27176" xml_f="27319" txt_i="17750" txt_f="17893">By comparison, genotyping can be carried out under any clinical circumstances with no limitations with respect to timing. In previous studies, </offsets><italic><offsets xml_i="27327" xml_f="27335" txt_i="17893" txt_f="17901">CYP2C19 </offsets><sup><offsets xml_i="27340" xml_f="27341" txt_i="17901" txt_f="17902">*</offsets></sup><offsets xml_i="27347" xml_f="27348" txt_i="17902" txt_f="17903">2</offsets></italic><offsets xml_i="27357" xml_f="27361" txt_i="17903" txt_f="17907"> or </offsets><italic><sup><offsets xml_i="27374" xml_f="27375" txt_i="17907" txt_f="17908">*</offsets></sup><offsets xml_i="27381" xml_f="27382" txt_i="17908" txt_f="17909">3</offsets></italic><offsets xml_i="27391" xml_f="27509" txt_i="17909" txt_f="18027"> carriers have been shown to have higher OPR and poor clinical outcomes with clopidogrel use after PCI, compared with </offsets><italic><offsets xml_i="27517" xml_f="27525" txt_i="18027" txt_f="18035">CYP2C19 </offsets><sup><offsets xml_i="27530" xml_f="27531" txt_i="18035" txt_f="18036">*</offsets></sup><offsets xml_i="27537" xml_f="27538" txt_i="18036" txt_f="18037">2</offsets></italic><offsets xml_i="27547" xml_f="27551" txt_i="18037" txt_f="18041"> or </offsets><italic><sup><offsets xml_i="27564" xml_f="27565" txt_i="18041" txt_f="18042">*</offsets></sup><offsets xml_i="27571" xml_f="27572" txt_i="18042" txt_f="18043">3</offsets></italic><offsets xml_i="27581" xml_f="27595" txt_i="18043" txt_f="18057"> non-carriers.</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="27627" xml_f="27630" txt_i="18057" txt_f="18060">28)</offsets></xref><offsets xml_i="27637" xml_f="27780" txt_i="18060" txt_f="18203"> However, genotyping also has its drawbacks. Clopidgrel is a pro-drug that is converted to an active metabolite in two hepatic steps involving </offsets><italic><offsets xml_i="27788" xml_f="27794" txt_i="18203" txt_f="18209">CYP1A2</offsets></italic><offsets xml_i="27803" xml_f="27805" txt_i="18209" txt_f="18211">, </offsets><italic><offsets xml_i="27813" xml_f="27816" txt_i="18211" txt_f="18214">2C9</offsets></italic><offsets xml_i="27825" xml_f="27827" txt_i="18214" txt_f="18216">, </offsets><italic><offsets xml_i="27835" xml_f="27839" txt_i="18216" txt_f="18220">2C19</offsets></italic><offsets xml_i="27848" xml_f="27850" txt_i="18220" txt_f="18222">, </offsets><italic><offsets xml_i="27858" xml_f="27863" txt_i="18222" txt_f="18227">3A4/5</offsets></italic><offsets xml_i="27872" xml_f="27886" txt_i="18227" txt_f="18241">, not only by </offsets><italic><offsets xml_i="27894" xml_f="27898" txt_i="18241" txt_f="18245">2C19</offsets></italic><offsets xml_i="27907" xml_f="27974" txt_i="18245" txt_f="18312">. To date, point-of-care clopidogrel genetic testing is limited to </offsets><italic><offsets xml_i="27982" xml_f="27989" txt_i="18312" txt_f="18319">CYP2C19</offsets></italic><offsets xml_i="27998" xml_f="28030" txt_i="18319" txt_f="18351"> single nucleotide polymorphism;</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="28062" xml_f="28065" txt_i="18351" txt_f="18354">12)</offsets></xref><xref ref-type="bibr" rid="B14"><offsets xml_i="28104" xml_f="28107" txt_i="18354" txt_f="18357">14)</offsets></xref><offsets xml_i="28114" xml_f="28123" txt_i="18357" txt_f="18366"> yet the </offsets><italic><offsets xml_i="28131" xml_f="28138" txt_i="18366" txt_f="18373">CYP2C19</offsets><sup><offsets xml_i="28143" xml_f="28144" txt_i="18373" txt_f="18374">*</offsets></sup><offsets xml_i="28150" xml_f="28151" txt_i="18374" txt_f="18375">2</offsets></italic><offsets xml_i="28160" xml_f="28251" txt_i="18375" txt_f="18466"> genotype only accounts for approximately 12% of the variation in the clopidogrel response.</offsets><xref ref-type="bibr" rid="B28"><offsets xml_i="28283" xml_f="28286" txt_i="18466" txt_f="18469">28)</offsets></xref><offsets xml_i="28293" xml_f="28387" txt_i="18469" txt_f="18563"> The feasibility of genotype-guided prasugrel use has been proven in a proof-of-concept trial,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="28419" xml_f="28422" txt_i="18563" txt_f="18566">14)</offsets></xref><offsets xml_i="28429" xml_f="28523" txt_i="18566" txt_f="18660"> but the clinical benefits of genotype-guided antiplatelet therapy has yet to be demonstrated.</offsets></p><p><offsets xml_i="28530" xml_f="28752" txt_i="18661" txt_f="18883">Although genetic testing and platelet function testing may provide additive information in selecting an antiplatelet regimen for patients undergoing PCI, their routine use is not recommended in current practice guidelines.</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="28783" xml_f="28785" txt_i="18883" txt_f="18885">2)</offsets></xref><offsets xml_i="28792" xml_f="29128" txt_i="18885" txt_f="19221"> Genotyping may be an improved guide for chronic antiplatelet therapy, while platelet function testing is more useful in acute settings. Nevertheless, the benefits of genotype- and phenotype-directed individualization of antiplatelet therapy to improve clinical outcomes requires validation though further randomized, controlled trials.</offsets></p><sec><title><offsets xml_i="29144" xml_f="29155" txt_i="19222" txt_f="19233">Limitations</offsets></title><p><offsets xml_i="29166" xml_f="29864" txt_i="19234" txt_f="19932">A potential limitation of the present study relates to the early termination of the trial due to the unavailability of the Verigene CLO assay during the study. Furthermore, the crossover rate from ticagrelor to clopidogrel was higher in the genotype- versus the phenotype-directed group, possibly due to the higher number of patients allocated ticagrelor in the genotype-directed group. Moreover, there was no standard care control group comparing genotype- versus phenotype-directed antiplatelet therapy. Finally, our analyses were based on a single determination of the PRU value, which is subject to random measurement error and may possibly have underestimated the strength of the associations.</offsets></p></sec><sec><title><offsets xml_i="29886" xml_f="29896" txt_i="19934" txt_f="19944">Conclusion</offsets></title><p><offsets xml_i="29907" xml_f="30061" txt_i="19945" txt_f="20099">In summary, tailoring the use of P2Y12 inhibitors based on point-of-care genetic and phenotypic testing may be effective in decreasing HOPR after 30 days.</offsets></p></sec></sec></body><back><ack><title>Acknowledgments</title><p>This work was supported by a research grant from the Korean Society of Circulation (2011-12).</p></ack><fn-group><fn fn-type="conflict"><p>The authors have no financial conflicts of interest.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yusuf</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><etal></etal></person-group><article-title>Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation</article-title><source>N Engl J Med</source><year>2001</year><volume>345</volume><fpage>494</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">11519503</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levine</surname><given-names>GN</given-names></name><name><surname>Bates</surname><given-names>ER</given-names></name><name><surname>Blankenship</surname><given-names>JC</given-names></name><etal></etal></person-group><article-title>2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions</article-title><source>Circulation</source><year>2011</year><volume>124</volume><fpage>2574</fpage><lpage>2609</lpage><pub-id pub-id-type="pmid">22064598</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>EW</given-names></name><name><surname>Wong</surname><given-names>CK</given-names></name><name><surname>Herbison</surname><given-names>P</given-names></name></person-group><article-title>Global Registry of Acute Coronary Events (GRACE) hospital discharge risk score accurately predicts long-term mortality post acute coronary syndrome</article-title><source></source><year>2007</year><volume>153</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">17174633</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Yoon</surname><given-names>JH</given-names></name><etal></etal></person-group><article-title>Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction</article-title><source>JACC Cardiovasc Interv</source><year>2012</year><volume>5</volume><fpage>259</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">22440490</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcucci</surname><given-names>R</given-names></name><name><surname>Gori</surname><given-names>AM</given-names></name><name><surname>Paniccia</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>237</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">19118249</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><etal></etal></person-group><article-title>The significance of clopidogrel low-responsiveness on stent thrombosis and cardiac death assessed by the verifynow p(2)y(12) assay in patients with acute coronary syndrome within 6 months after drug-eluting stent implantation</article-title><source>Korean Circ J</source><year>2009</year><volume>39</volume><fpage>512</fpage><lpage>518</lpage><pub-id pub-id-type="pmid">20049136</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wiviott</surname><given-names>SD</given-names></name><name><surname>Braunwald</surname><given-names>E</given-names></name><name><surname>McCabe</surname><given-names>CH</given-names></name><etal></etal></person-group><article-title>Prasugrel versus clopidogrel in patients with acute coronary syndromes</article-title><source>N Engl J Med</source><year>2007</year><volume>357</volume><fpage>2001</fpage><lpage>2015</lpage><pub-id pub-id-type="pmid">17982182</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1045</fpage><lpage>1057</lpage><pub-id pub-id-type="pmid">19717846</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patti</surname><given-names>G</given-names></name><name><surname>Nusca</surname><given-names>A</given-names></name><name><surname>Mangiacapra</surname><given-names>F</given-names></name><name><surname>Gatto</surname><given-names>L</given-names></name><name><surname>D'Ambrosio</surname><given-names>A</given-names></name><name><surname>Di Sciascio</surname><given-names>G</given-names></name></person-group><article-title>Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study</article-title><source>J Am Coll Cardiol</source><year>2008</year><volume>52</volume><fpage>1128</fpage><lpage>1133</lpage><pub-id pub-id-type="pmid">18804738</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>MJ</given-names></name><name><surname>Berger</surname><given-names>PB</given-names></name><name><surname>Teirstein</surname><given-names>PS</given-names></name><etal></etal></person-group><article-title>Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial</article-title><source>JAMA</source><year>2011</year><volume>305</volume><fpage>1097</fpage><lpage>1105</lpage><pub-id pub-id-type="pmid">21406646</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>MJ</given-names></name></person-group><article-title>Bedside evaluation of thienopyridine antiplatelet therapy</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>2625</fpage><lpage>2632</lpage><pub-id pub-id-type="pmid">19451364</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buchan</surname><given-names>BW</given-names></name><name><surname>Peterson</surname><given-names>JF</given-names></name><name><surname>Cogbill</surname><given-names>CH</given-names></name><etal></etal></person-group><article-title>Evaluation of a microarray-based genotyping assay for the rapid detection of cytochrome P450 2C19 <sup>*</sup>2 and <sup>*</sup>3 polymorphisms from whole blood using nanoparticle probes</article-title><source>Am J Clin Pathol</source><year>2011</year><volume>136</volume><fpage>604</fpage><lpage>608</lpage><pub-id pub-id-type="pmid">21917683</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trenk</surname><given-names>D</given-names></name><name><surname>Stone</surname><given-names>GW</given-names></name><name><surname>Gawaz</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>59</volume><fpage>2159</fpage><lpage>2164</lpage><pub-id pub-id-type="pmid">22520250</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roberts</surname><given-names>JD</given-names></name><name><surname>Wells</surname><given-names>GA</given-names></name><name><surname>Le May</surname><given-names>MR</given-names></name><etal></etal></person-group><article-title>Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial</article-title><source>Lancet</source><year>2012</year><volume>379</volume><fpage>1705</fpage><lpage>1711</lpage><pub-id pub-id-type="pmid">22464343</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Tantry</surname><given-names>US</given-names></name><name><surname>Marcucci</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate</article-title><source>J Am Coll Cardiol</source><year>2010</year><volume>56</volume><fpage>919</fpage><lpage>933</lpage><pub-id pub-id-type="pmid">20828644</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ko</surname><given-names>YG</given-names></name><name><surname>Suh</surname><given-names>JW</given-names></name><name><surname>Kim</surname><given-names>BH</given-names></name><etal></etal></person-group><article-title>Comparison of 2 point-of-care platelet function tests, VerifyNow Assay and Multiple Electrode Platelet Aggregometry, for predicting early clinical outcomes in patients undergoing percutaneous coronary intervention</article-title><source>Am Heart J</source><year>2011</year><volume>161</volume><fpage>383</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">21315223</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>JJ</given-names></name><name><surname>Jeon</surname><given-names>KH</given-names></name><etal></etal></person-group><article-title>Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans</article-title><source>Cardiovasc Ther</source><year>2012</year><volume>30</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">21129165</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jannetto</surname><given-names>PJ</given-names></name><name><surname>Buchan</surname><given-names>BW</given-names></name><name><surname>Vaughan</surname><given-names>KA</given-names></name><etal></etal></person-group><article-title>Real-time detection of influenza a, influenza B, and respiratory syncytial virus a and B in respiratory specimens by use of nanoparticle probes</article-title><source>J Clin Microbiol</source><year>2010</year><volume>48</volume><fpage>3997</fpage><lpage>4002</lpage><pub-id pub-id-type="pmid">20826644</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saracini</surname><given-names>C</given-names></name><name><surname>Vestrini</surname><given-names>A</given-names></name><name><surname>Galora</surname><given-names>S</given-names></name><name><surname>Armillis</surname><given-names>A</given-names></name><name><surname>Abbate</surname><given-names>R</given-names></name><name><surname>Giusti</surname><given-names>B</given-names></name></person-group><article-title>Pharmacogenetics of clopidogrel: comparison between a standard and a rapid genetic testing</article-title><source>Genet Test Mol Biomarkers</source><year>2012</year><volume>16</volume><fpage>500</fpage><lpage>503</lpage><pub-id pub-id-type="pmid">22239289</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehran</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>SV</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><etal></etal></person-group><article-title>Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium</article-title><source>Circulation</source><year>2011</year><volume>123</volume><fpage>2736</fpage><lpage>2747</lpage><pub-id pub-id-type="pmid">21670242</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Tanguay</surname><given-names>JF</given-names></name><name><surname>Eikelboom</surname><given-names>JW</given-names></name><etal></etal></person-group><article-title>Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial</article-title><source>Lancet</source><year>2010</year><volume>376</volume><fpage>1233</fpage><lpage>1243</lpage><pub-id pub-id-type="pmid">20817281</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>KY</given-names></name><name><surname>Rha</surname><given-names>SW</given-names></name><name><surname>Li</surname><given-names>YJ</given-names></name><etal></etal></person-group><article-title>Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention</article-title><source>Circulation</source><year>2009</year><volume>119</volume><fpage>3207</fpage><lpage>3214</lpage><pub-id pub-id-type="pmid">19528339</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suh</surname><given-names>JW</given-names></name><name><surname>Lee</surname><given-names>SP</given-names></name><name><surname>Park</surname><given-names>KW</given-names></name><etal></etal></person-group><article-title>Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON ischemic complication after drug-eluting stenT implantation) trial</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="pmid">21232664</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eikelboom</surname><given-names>JW</given-names></name><name><surname>Mehta</surname><given-names>SR</given-names></name><name><surname>Anand</surname><given-names>SS</given-names></name><name><surname>Xie</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>KA</given-names></name><name><surname>Yusuf</surname><given-names>S</given-names></name></person-group><article-title>Adverse impact of bleeding on prognosis in patients with acute coronary syndromes</article-title><source>Circulation</source><year>2006</year><volume>114</volume><fpage>774</fpage><lpage>782</lpage><pub-id pub-id-type="pmid">16908769</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campo</surname><given-names>G</given-names></name><name><surname>Parrinello</surname><given-names>G</given-names></name><name><surname>Ferraresi</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Prospective evaluation of onclopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome</article-title><source>J Am Coll Cardiol</source><year>2011</year><volume>57</volume><fpage>2474</fpage><lpage>2483</lpage><pub-id pub-id-type="pmid">21679849</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ahn</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Sung</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><name><surname>Yoon</surname><given-names>J</given-names></name></person-group><article-title>Intra-individual variability of residual platelet reactivity assessed by the VerifyNow-P2Y12 assay in patients with clopidogrel resistance after percutaneous coronary intervention</article-title><source>Platelets</source><year>2011</year><volume>22</volume><fpage>305</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">21480769</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Cuisset</surname><given-names>T</given-names></name><name><surname>Rangé</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>Bedside monitoring to adjust antiplatelet therapy for coronary stenting</article-title><source>N Engl J Med</source><year>2012</year><volume>367</volume><fpage>2100</fpage><lpage>2109</lpage><pub-id pub-id-type="pmid">23121439</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shuldiner</surname><given-names>AR</given-names></name><name><surname>O'Connell</surname><given-names>JR</given-names></name><name><surname>Bliden</surname><given-names>KP</given-names></name><etal></etal></person-group><article-title>Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy</article-title><source>JAMA</source><year>2009</year><volume>302</volume><fpage>849</fpage><lpage>857</lpage><pub-id pub-id-type="pmid">19706858</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mega</surname><given-names>JL</given-names></name><name><surname>Hochholzer</surname><given-names>W</given-names></name><name><surname>Frelinger</surname><given-names>AL</given-names><suffix>3rd</suffix></name><etal></etal></person-group><article-title>Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease</article-title><source>JAMA</source><year>2011</year><volume>306</volume><fpage>2221</fpage><lpage>2228</lpage><pub-id pub-id-type="pmid">22088980</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Schematic diagram of the study. <italic>CYP</italic>: cytochrome, PCI: percutaneous coronary intervention, PRU: P2Y<sub>12</sub> reaction unit, ST-ACS: ST-elevation acute coronary syndromes.</p></caption><graphic xlink:href="kcj-43-541-g001"></graphic></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Comparison of the on-treatment of platelet reactivity (OPR) between baseline versus the one-month follow-up (D 30) according to the personalization strategy for antiplatelet therapy (A) and the type of antiplatelet agent (B). OPR decreased following both genotype- and phenotype-directed therapies (242±83 vs. 109±90, p&lt;0.001 in the genotype-directed group; 216±74 vs. 109±90, p=0.001 in the phenotype-directed group). Five subjects (16.2%) in the genotype-directed group and one (3.3%) in the phenotype-directed group had HOPR after 30 days of treatment (p=0.086). After 30 days of treatment, OPR was lower (49±30 vs. 179±77, p&lt;0.001) among patients administered ticagrelor as compared to clopidogrel. HOPR: high OPR.</p></caption><graphic xlink:href="kcj-43-541-g002"></graphic></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics</p></caption><graphic xlink:href="kcj-43-541-i001"></graphic><table-wrap-foot><fn><p>Values are expressed as number (%) or mean±SD. ACE: angiotensin-converting enzyme, ARB: angiotensin receptor blocker, NSTEMI: non-ST-segment elevation myocardial infarction</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Comparison of on-treatment platelet reactivity</p></caption><graphic xlink:href="kcj-43-541-i002"></graphic><table-wrap-foot><fn><p><sup>*</sup>Sixty one patients (95.3%) had follow-up VerifyNow P2Y12 assay: 31 in the genotype-directed group and 30 in the phenotype-directed group. <italic>CYP</italic>: cytochrome, PRU: P2Y<sub>12</sub> reaction unit</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>On-treatment platelet reactivity according to <italic>CYP2C19</italic> genotype</p></caption><graphic xlink:href="kcj-43-541-i003"></graphic><table-wrap-foot><fn><p><sup>*</sup>p=0.039 vs. <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>1</italic> or <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>17</italic>, <sup>†</sup>p=0.019 vs. <italic>CYP<sup>*</sup>2</italic> or <italic><sup>*</sup>3</italic> heterozygote, <sup>‡</sup>p=0.007 vs. <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>1</italic> or <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>17</italic>, <sup>§</sup>p=0.046 vs. <italic>CYP<sup>*</sup>2</italic> or <italic><sup>*</sup>3</italic> heterozygote, <sup>∥</sup>Follow-up VerifyNow P2Y12 assay was not available in one patient with <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>1</italic> or <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>17</italic> and in 3 patients with <italic>CYP<sup>*</sup>2</italic> or <italic><sup>*</sup>3</italic> heterozygote, <sup>¶</sup>p=0.004 vs. <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>1</italic> or <italic>CYP<sup>*</sup>1</italic>/<italic><sup>*</sup>17</italic>. PRU: P2Y<sub>12</sub> reaction unit, <italic>CYP</italic>: cytochrome</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Comparison of on-treatment platelet reactivity according to type of P2Y<sub>12</sub> inhibitor</p></caption><graphic xlink:href="kcj-43-541-i004"></graphic><table-wrap-foot><fn><p><sup>*</sup>At 30 days, 36 patients were given clopidogrel and 25 patients were given ticagrelor. PRU: P2Y<sub>12</sub> reaction unit, <italic>CYP</italic>: cytochrome</p></fn></table-wrap-foot></table-wrap></floats-group></article>